Matthew Roden

Matthew Roden is President, Chief Executive Officer & Director at Aktis Oncology, Inc. since 2020.
Director at Orna Therapeutics, Inc. since 2024.
Director at ReNAgade Therapeutics, Inc. since 2023.
Entrepreneur Partner at MPM BioImpact LLC since 2020.
Former Chairman at Turmeric Acquisition Corp.
from 2020 to 2022.
Executive Director & Analyst at UBS Securities LLC from 2010 to 2016.
Director at BioNJ, Inc. Former Director at Nextpoint Therapeutics, Inc. from 2020 to 2024.
Independent Director at iTeos Therapeutics, Inc. from 2020 to 2023.
President & Director at Celgene Corp.
Senior Vice President & Head-Enterprise Strategy at Bristol Myers Squibb Co. from 2019 to 2020.
Associate Analyst at Credit Suisse Securities (USA) LLC (Broker) in 2006.
Analyst at Merrill Lynch, Pierce, Fenner & Smith, Inc. in 2010.
Associate Analyst at JPMorgan Securities LLC in 2009.
Associate at Credit Suisse Securities (USA) LLC from 2005 to 2006.
Head-Global Biotechnology Equity Research at UBS Investment Bank (New York) from 2010 to 2016.
Education includes undergraduate degree from George Mason University, graduate degree from Georgetown University, and doctorate from Albert Einstein College of Medicine, Inc.